CG ONCOLOGY, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.5 USD | -5.06% |
|
-21.42% | 0.00% |
Valuation
| Fiscal Period: December | 2024 | 2025 | 2026 |
|---|---|---|---|
| Capitalization 1 | 1,899 | - | - |
| Enterprise Value (EV) 1 | 1,694 | 1,687 | 1,395 |
| P/E ratio | -16.7 x | -14.1 x | -16 x |
| Yield | - | - | - |
| Capitalization / Revenue | - | - | 24.2 x |
| EV / Revenue | - | - | 17.8 x |
| EV / EBITDA | -17.3 x | -15.9 x | -17.9 x |
| EV / FCF | -15.8 x | -11.7 x | -9.77 x |
| FCF Yield | -6.33% | -8.53% | -10.2% |
| Price to Book | 8.77 x | 15.2 x | 15.7 x |
| Nbr of stocks (in thousands) | 66,640 | - | - |
| Reference price 2 | 28.50 | 28.50 | 28.50 |
| Announcement Date | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 78.42 |
| EBITDA 1 | - | -55.43 | -97.94 | -106.4 | -78.08 |
| EBIT 1 | - | -55.45 | -103 | -123.2 | -136.7 |
| Operating Margin | - | - | - | - | -174.33% |
| Earnings before Tax (EBT) 1 | - | -48.61 | -96.19 | -121.6 | -139.4 |
| Net income 1 | -35.44 | -48.61 | -96.19 | -107.3 | -123.3 |
| Net margin | - | - | - | - | -157.29% |
| EPS 2 | -11.73 | -15.65 | -1.705 | -2.022 | -1.787 |
| Free Cash Flow 1 | - | -45.68 | -107.2 | -143.9 | -142.7 |
| FCF margin | - | - | - | - | -182.01% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 10/27/23 | 3/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 0.529 | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | -18.93 | -22.47 | -24.9 | -27.1 | -29.5 | - | - |
| Operating Margin | - | -4,247.45% | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -16.93 | -24.9 | -27.1 | -29.5 | - | - |
| Net income 1 | - | -16.93 | -24.9 | -27.1 | -29.5 | - | - |
| Net margin | - | -3,200.76% | - | - | - | - | - |
| EPS 2 | - | -0.3600 | -0.4075 | -0.4475 | -0.4750 | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 3/26/24 | 5/9/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | 188 | 206 | 212 | 504 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -45.7 | -107 | -144 | -143 |
| ROE (net income / shareholders' equity) | - | - | -220% | -52.1% | -13.2% |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share 2 | - | -28.40 | 3.250 | 1.880 | 1.820 |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | - | 2.09 | 2.4 | 2.85 |
| Capex / Sales | - | - | - | - | 3.63% |
| Announcement Date | 10/27/23 | 3/26/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
28.5
USD
Average target price
66.8
USD
Spread / Average Target
+134.39%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 1.9B | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- CGON Stock
- Financials CG Oncology, Inc.